这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 low status in early-stage invasive lobular carcinoma of the breast: associate...
4、Collins DM, Conlon NT, Kannan S, et al. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Cancers (Basel). 20...
PERJETA should be used as part of a complete treatment regimen for early breast cancer. use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back. PERJETA® (pertuzumab) is a prescription medicine approved for use in ...
[1] Bazell R. Her-2: The making of herceptin, a revolutionary treatment for breast cancer[M]. Random House, 2011. [2] EsTEva F J, Hortobagyi G N. Gaining ground on breast cancer[J]. Scientific American, 2008, 298(6): 58-65. [3] Ullrich A, Coussens L, Hayflick J S, et al....
Herceptin is approved for the treatment of adults with early-stage breast cancer that isHumanEpidermal growth factorReceptor2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the ...
[1]https://www.onclive.com/view/antibody-drug-conjugates-expand-her2-breast-cancer-treatment-options [2]DS-8201a in pre-treated HER2 breast cancer that cannot be surgically removed or has spread [DESTINY-Breast02]. ClinicalTrials.gov. Updated August 12, 2022. Accessed November 28, 2022. ...
Breast Cancer Research and Treatment (2019) 177:237–250 https://doi.org/10.1007/s10549-019-05303-y REVIEW HER2+ breast cancer treatment and cardiotoxicity: monitoring and management Guy Jerusalem1 · Patrizio Lancellotti2 · Sung‑Bae Kim3 Received: 21 May 2019 / ...
Methods for the treatment of HER2-positive breast cancer are provided by neoadjuvant administration of pertuzumab and trastuzumab in combination with anthracycline-based chemotherapy. In particular, the methods concerns the treatment patients with HER2-positive, locally advanced, inflammatory, or early-stage...
DESTINY-Breast03是一项实用的临床研究,比较了德曲妥珠单抗(T-Dxd)与恩美曲妥珠单抗(T-DM1)在HER2阳性乳腺癌患者中的疗效差异,该研究为德曲妥珠单抗二线治疗奠定了基础。 ▲基于DESTINY-Breast03研究的结果,FDA批准德曲妥珠单抗用于治疗既往在转移性疾病阶段接受过至少一种系统治疗的,或在辅助化疗期间或完成辅助化疗之后...
[2].Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 1;26(5):1105-1113.[3].Rugo HS, Rumble RB, Macrae E, ...